Abstract | OBJECTIVE: DESIGN: Nonrandomized, prospective clinical trial. PATIENTS: Forty-one patients with moderate-severe hirsutism were included in the study. INTERVENTION: Hirsute patients received 250 mg/d flutamide for a period of 6 months. MAIN OUTCOME MEASURES:
Hirsutism score, FSH, LH, E2, total T, free T, androstenedione, DHEAS, PRL, 17-hydroxyprogesterone, and sex hormone-binding globulin levels were detected in all the patients before treatment and every 3 months during treatment. RESULTS: Treatment with the antiandrogen flutamide resulted in a particularly rapid and marked decrease in the hirsutism score, which decreased from 17.48 +/- 5.35 to 5.07 +/- 2.89 after 6 months. No significant changes in the levels of hormone and no serious side effects were observed in the study. CONCLUSION:
|
Authors | I I Müderris, F Bayram, Y Sahin, F Keleştimur, A Tutuş, D Ayata |
Journal | Fertility and sterility
(Fertil Steril)
Vol. 66
Issue 2
Pg. 220-2
(Aug 1996)
ISSN: 0015-0282 [Print] United States |
PMID | 8690105
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Androgen Antagonists
- Estrogens
- Testosterone
- Androstenedione
- Progesterone
- Flutamide
- Luteinizing Hormone
- Follicle Stimulating Hormone
|
Topics |
- Adolescent
- Adult
- Androgen Antagonists
(therapeutic use)
- Androstenedione
(blood)
- Dose-Response Relationship, Drug
- Estrogens
(blood)
- Female
- Flutamide
(therapeutic use)
- Follicle Stimulating Hormone
(blood)
- Hirsutism
(blood, drug therapy)
- Humans
- Luteinizing Hormone
(blood)
- Progesterone
(blood)
- Prospective Studies
- Testosterone
(blood)
|